Article
Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial.
Antiviral therapy - 1 Jan 2018
Lee Sae Hwan, Cheon Gab Jin, Kim Hong Soo, Kim Sang Gyune, Kim Young Seok, Jeong Soung Won, Jang Jae Young, Kim Boo Sung, Jun Baek Gyu, Don Kim Young, Jun Dae Won, Sohn Joo Hyun, Kim Tae Yeob, Lee Byung Seok
Abstract excerpt
BACKGROUND: A complete virological response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging HBV mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therapy in patients with suboptimal responses to long-term lamivudine-adefovir dipivoxil (LAM-ADV)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.